Companies that have failed to challenge the patent of Boryung’s antihypertensive combo drug ‘Dukarb (fimasartan+amlodipine)’ are continuing on their challenge with a second trial.

As the companies are also working to invalidate the patent apart from the trial being conducted to avoid the patent, this two-track challenge on a single patent is expected to continue on for a while.

According to industry sources on the 6th, Arlico Pharm, Hutex Korea Pharmaceutical, Shinpoong Pharm, and Hana Pharm filed an appeal against a ruling to the Patent Court of Korea. In other words, the four companies are taking the matter to the next trial, dissatisfied with the ruling of defeat given to t